Glucagon receptor signaling regulates weight loss via central KLB receptor complexes

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 1× · see citing works

Global burden of obesity in 2005 and projections to 2030

Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319 · see citing works

FGF-21 as a novel metabolic regulator

Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · see citing works

The Fibroblast Growth Factor signaling pathway

Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050 · cited 1× · see citing works

FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis

Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478 · see citing works

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151 · see citing works

Fibroblast Growth Factor 21 Corrects Obesity in Mice

Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031 · see citing works

Long-term Drug Treatment for Obesity: A Systematic and Clinical Review

Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876 · see citing works

Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over

Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831 · see citing works

FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response

Potthoff, M. J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B. N., Mangelsdorf, D. J., Kliewer, S. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904187106 · Cited by 704 · see citing works

Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult Mouse

Fon Tacer, K., Bookout, A. L., Ding, X., Kurosu, H., John, G. B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D. J., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0142 · Cited by 700 · see citing works

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641 · see citing works

βKlotho is required for metabolic activity of fibroblast growth factor 21

Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Goetz, R., Eliseenkova, A. V., Mohammadi, M., & Kuro-o, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701600104 · Cited by 617 · see citing works

The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic

Geng, L., Lam, K. S. L., & Xu, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0386-0 · Cited by 607 · see citing works

Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding

Markan, K. R., Naber, M. C., Ameka, M. K., Anderegg, M. D., Mangelsdorf, D. J., Kliewer, S. A., Mohammadi, M., & Potthoff, M. J. (2014) · Diabetes · doi:10.2337/db14-0595 · Cited by 590 · see citing works

Fibroblast Growth Factor 19 Increases Metabolic Rate and Reverses Dietary and Leptin-Deficient Diabetes

Fu, L., John, L. M., Adams, S. H., Yu, X. X., Tomlinson, E., Renz, M. E., Williams, P. M., Soriano, R. H., Corpuz, R. T., Moffat, B., et al. (2004) · Endocrinology · doi:10.1210/en.2003-1671 · Cited by 580 · see citing works

FGF21 regulates metabolism and circadian behavior by acting on the nervous system

Bookout, A. L., de Groot, M. H. M., Owen, B. M., Lee, S., Gautron, L., Lawrence, H. L., Ding, X., Elmquist, J. K., Takahashi, J. S., Mangelsdorf, D. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3249 · Cited by 545 · see citing works

FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss

Owen, B. M., Ding, X., Morgan, D. A., Coate, K. C., Bookout, A. L., Rahmouni, K., Kliewer, S. A., & Mangelsdorf, D. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.012 · Cited by 523 · see citing works

Fibroblast Growth Factor-21 Improves Pancreatic β-Cell Function and Survival by Activation of Extracellular Signal–Regulated Kinase 1/2 and Akt Signaling Pathways

Wente, W., Efanov, A. M., Brenner, M. B., Kharitonenkov, A., Koster, A. M., Sandusky, G. E., Sewing, S., Treinies, I., Zitzer, H., & Gromada, J. (2006) · Diabetes · doi:10.2337/db05-1435 · Cited by 497 · see citing works

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409 · see citing works

Obesity and its comorbid conditions

Khaodhiar, L., McCowen, K. C., & Blackburn, G. L. (1999) · Clinical cornerstone · doi:10.1016/s1098-3597(99)90002-9 · Cited by 403 · see citing works

βKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism

Ding, X., Boney-Montoya, J., Owen, B. M., Bookout, A. L., Coate, K. C., Mangelsdorf, D. J., & Kliewer, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.08.002 · Cited by 403 · see citing works

Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver

Hotta, Y., Nakamura, H., Konishi, M., Murata, Y., Takagi, H., Matsumura, S., Inoue, K., Fushiki, T., & Itoh, N. (2009) · Endocrinology · doi:10.1210/en.2009-0119 · Cited by 352 · see citing works

βKlotho Is Required for Fibroblast Growth Factor (FGF) 21 Signaling through FGF Receptor (FGFR) 1c and FGFR3c

Suzuki, M., Uehara, Y., Motomura-Matsuzaka, K., Oki, J., Koyama, Y., Kimura, M., Asada, M., Komi-Kuramochi, A., Oka, S., & Toru, T. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0313 · Cited by 345 · see citing works

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models—association with liver and adipose tissue effects

Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2009 · Cited by 340 · see citing works

Obesity and Disease Management: Effects of Weight Loss on Comorbid Conditions

Anderson, J. W., & Konz, E. C. (2001) · Obesity Research · doi:10.1038/oby.2001.138 · Cited by 330 · see citing works

FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms

BonDurant, L. D., Ameka, M., Naber, M. C., Markan, K. R., Idiga, S. O., Acevedo, M. R., Walsh, S. A., Ornitz, D. M., & Potthoff, M. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.005 · Cited by 330 · see citing works

FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho

Kharitonenkov, A., Dunbar, J. D., Bina, H. A., Bright, S. W., Moyers, J. S., Zhang, C., Ding, L., Micanovic, R., Mehrbod, S. F., Knierman, M. D., et al. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21357 · Cited by 329 · see citing works

FGF21 gene therapy as treatment for obesity and insulin resistance

Jiménez, V., Jambrina, C., Casana, E., Sacristan, V., MUÑOZ, S. A., Darriba, S., Rodó, J., Mallol, C., García, M., León, X., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708791 · Cited by 319 · see citing works

Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese Rats

Sarruf, D. A., Thaler, J. P., Morton, G. J., German, J. P., Fischer, J. D., Ogimoto, K., & Schwartz, M. W. (2010) · Diabetes · doi:10.2337/db09-1878 · Cited by 287 · see citing works

Liver-specific Activities of FGF19 Require Klotho beta

Lin, B. C., Wang, M., Blackmore, C. A., & Desnoyers, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704244200 · Cited by 284 · see citing works

The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue

Adams, A. C., Yang, C., Coskun, T., Cheng, C. C., Gimeno, R. E., Luo, Y., & Kharitonenkov, A. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2012.08.007 · Cited by 266 · see citing works

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245 · see citing works

Cellular Mechanisms by Which FGF21 Improves Insulin Sensitivity in Male Mice

Camporez, J. P., Jornayvaz, F. R., Petersen, M. C., Pesta, D. H., Guigni, B. A., Serr, J., Zhang, D., Kahn, M., Samuel, V. T., Jurczak, M. J., et al. (2013) · Endocrinology · doi:10.1210/en.2013-1191 · Cited by 226 · see citing works

Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity

Mashili, F. L., Austin, R. L., Deshmukh, A. S., Fritz, T., Caidahl, K., Bergdahl, K., Zierath, J. R., Chibalin, A., Moller, D. E., Kharitonenkov, A., et al. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1177 · Cited by 222 · see citing works

Glucagon Receptor Signaling and Lipid Metabolism

Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00413 · Cited by 218 · see citing works

Exercise Alleviates Obesity-Induced Metabolic Dysfunction via Enhancing FGF21 Sensitivity in Adipose Tissues

Geng, L., Liao, B., Jin, L., Huang, Z. P., Triggle, C. R., Ding, H., Zhang, J., Huang, Y., Lin, Z., & Xu, A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.014 · Cited by 201 · see citing works

Fibroblast Growth Factor-19 Action in the Brain Reduces Food Intake and Body Weight and Improves Glucose Tolerance in Male Rats

Ryan, K. K., Kohli, R., Gutierrez-Aguilar, R., Gaitonde, S. G., Woods, S. C., & Seeley, R. J. (2013) · Endocrinology · doi:10.1210/en.2012-1891 · Cited by 185 · see citing works

FGF21 Requires βklotho to Act In Vivo

Adams, A. C., Cheng, C. C., Coskun, T., & Kharitonenkov, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049977 · Cited by 181 · see citing works

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB

Yang, C., Jin, C., Li, X., Wang, F., McKeehan, W. L., & Luo, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033870 · Cited by 173 · see citing works

Circadian Rhythm of Circulating Fibroblast Growth Factor 21 Is Related to Diurnal Changes in Fatty Acids in Humans

Yu, H., Xia, F., Lam, K. S., Wang, Y., Bao, Y., Zhang, J., Gu, Y., Zhou, P., Lu, J., Jia, W., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155184 · Cited by 170 · see citing works

Glucagon lowers glycemia when β cells are active

Capozzi, M. E., Wait, J. B., Koech, J., Gordon, A. N., Coch, R. W., Svendsen, B., Finan, B., D’Alessio, D. A., & Campbell, J. E. (2019) · JCI Insight · doi:10.1172/jci.insight.129954 · Cited by 168 · see citing works

FGF21 Signals to Glutamatergic Neurons in the Ventromedial Hypothalamus to Suppress Carbohydrate Intake

Jensen-Cody, S. O., Flippo, K. H., Claflin, K. E., Yavuz, Y., Sapouckey, S. A., Walters, G. C., Usachev, Y. M., Atasoy, D., Gillum, M. P., & Potthoff, M. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.008 · Cited by 166 · see citing works

Impact of weight loss on Health-Related Quality of Life

Fontaine, K. R., Barofsky, I., Andersen, R. E., Bartlett, S. J., Wiersema, L., Cheskin, L. J., & Franckowiak, S. C. (1999) · Quality of Life Research · doi:10.1023/a:1008835602894 · Cited by 162 · see citing works

Health-related quality of life following a clinical weight loss intervention among overweight and obese adults: intervention and 24 month follow-up effects

Blissmer, B. J., Riebe, D. A., Dye, G., Ruggiero, L., Greene, G. W., & Caldwell, M. J. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-43 · Cited by 160 · see citing works

Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1

Samms, R. J., Smith, D. P., Cheng, C. C., Antonellis, P. P., Perfield, J. W., Kharitonenkov, A., Gimeno, R. E., & Adams, A. C. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.046 · Cited by 154 · see citing works

FGF21 mediates the thermogenic and insulin-sensitizing effects of dietary methionine restriction but not its effects on hepatic lipid metabolism

Wanders, D., Forney, L. A., Stone, K. P., Burk, D. H., Pierse, A., & Gettys, T. W. (2017) · Diabetes · doi:10.2337/db16-1212 · Cited by 137 · see citing works

Naringenin Prevents Obesity, Hepatic Steatosis, and Glucose Intolerance in Male Mice Independent of Fibroblast Growth Factor 21

Assini, J. M., Mulvihill, E. E., Burke, A. C., Sutherland, B. G., Telford, D. E., Chhoker, S. S., Sawyez, C. G., Drangova, M., Adams, A. C., Kharitonenkov, A., et al. (2015) · Endocrinology · doi:10.1210/en.2014-2003 · Cited by 119 · see citing works

Lipid Extraction from Mouse Feces

Kraus, D., Yang, Q., & Kahn, B. B. (2015) · BIO-PROTOCOL · doi:10.21769/bioprotoc.1375 · Cited by 109 · see citing works

Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo

Adams, A. C., Coskun, T., Irizarry Rovira, A. R., Schneider, M. A., Raches, D. W., Micanovic, R., Bina, H. A., Dunbar, J. D., & Kharitonenkov, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038438 · Cited by 109 · see citing works

CNS Leptin Action Modulates Immune Response and Survival in Sepsis

Tschöp, J., Nogueiras, R., Lockie, S. H., Kasten, K. R., Castañeda, T. R., Huber, N., Guanciale, K., Pérez–Tilve, D., Habegger, K. M., Ottaway, N., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4875-09.2010 · Cited by 98 · see citing works

Fibroblast growth factor 21 night watch: advances and uncertainties in the field

Kharitonenkov, A., & DiMarchi, R. D. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12580 · Cited by 97 · see citing works

Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21

Kim, T., Nason, S., Holleman, C., Pepin, M., Wilson, L., Berryhill, T. F., Wende, A. R., Steele, C., Young, M. E., Barnes, S., et al. (2018) · Diabetes · doi:10.2337/db17-1502 · Cited by 97 · see citing works

Glucagon Control on Food Intake and Energy Balance

Al–Massadi, O., Fernø, J., Diéguez, C., Nogueiras, R., & Quiñones, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163905 · Cited by 89 · see citing works

FGF21 as an Endocrine Regulator in Lipid Metabolism: From Molecular Evolution to Physiology and Pathophysiology

Murata, Y., Konishi, M., & Itoh, N. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/981315 · Cited by 85 · see citing works

Glucagon Stimulates Hepatic FGF21 Secretion through a PKA- and EPAC-Dependent Posttranscriptional Mechanism

Cyphert, H. A., Alonge, K. M., Ippagunta, S. M., & Hillgartner, F. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094996 · Cited by 80 · see citing works

An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity

Babaknejad, N., Nayeri, H., Hemmati, R., Bahrami, S., & Esmaillzadeh, A. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0623-2909 · Cited by 70 · see citing works

Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents

Kim, T., Holleman, C. L., Nason, S. R., Arble, D. M., Ottaway, N., Chabenne, J. R., Loyd, C., Kim, J., Sandoval, D. A., Drucker, D. J., et al. (2018) · Diabetes · doi:10.2337/db18-0068 · Cited by 69 · see citing works

The central fibroblast growth factor receptor/beta klotho system: Comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform

Hultman, K., Scarlett, J. M., Baquero, A. F., Cornea, A. M., Zhang, Y., Salinas, C. B. G., Brown, J. M., Morton, G. J., Whalen, E. J., Grove, K. L., et al. (2019) · The Journal of Comparative Neurology · doi:10.1002/cne.24668 · Cited by 65 · see citing works

FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes

Chen, M. Z., Chang, J. C., Zavala-Solorio, J., Kates, L., Thai, M., Ogasawara, A., Bai, X., Flanagan, S., Nunez, V., Phamluong, K., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.003 · Cited by 58 · see citing works

β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue

Somm, E., Henry, H., Bruce, S. J., Aeby, S., Rosikiewicz, M., Sykiotis, G. P., Asrih, M., Jornayvaz, F. R., Denechaud, P., Albrecht, U., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91809 · Cited by 57 · see citing works

The impact of weight loss on health-related quality-of-life: implications for cost-effectiveness analyses

Rothberg, A. E., McEwen, L. N., Kraftson, A. T., Neshewat, G. M., Fowler, C. E., Burant, C., & Herman, W. H. (2013) · Quality of Life Research · doi:10.1007/s11136-013-0557-8 · Cited by 55 · see citing works

Pharmacological Approaches in the Treatment and Maintenance of Weight Loss

Gaal, L. V., & Dirinck, E. L. (2016) · Diabetes Care · doi:10.2337/dcs15-3016 · Cited by 53 · see citing works

Disruption of circadian rhythmicity and suprachiasmatic action potential frequency in a mouse model with constitutive activation of glycogen synthase kinase 3

Paul, J. R., Johnson, R. L., Jope, R. S., & Gamble, K. L. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.08.047 · Cited by 51 · see citing works

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity

Agrawal, A., Parlee, S. D., Pérez–Tilve, D., Li, P., Pan, J. H., Mroz, P. A., Hansen, A. M. K., Andersen, B., Finan, B., Kharitonenkov, A., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.003 · Cited by 42 · see citing works

The Nuclear Receptor Rev-erbα Regulates Adipose Tissue-specific FGF21 Signaling

Jager, J., Wang, F., Fang, B., Lim, H., Peed, L. C., Steger, D. J., Won, K., Kharitonenkov, A., Adams, A. C., & Lazar, M. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.719120 · Cited by 35 · see citing works

FGF21 as a Therapeutic Reagent

Zhao, Y., Dunbar, J. D., & Kharitonenkov, A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0887-1_14 · Cited by 30 · see citing works

Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression

Nason, S. R., Kim, T., ANTIPENKO, J. P., Finan, B., DiMarchi, R. D., Hunter, C. S., & Habegger, K. M. (2019) · Endocrinology · doi:10.1210/endocr/bqz013 · Cited by 26 · see citing works

Differential receptor selectivity of the FGF15/FGF19 orthologues determines distinct metabolic activities in db/db mice

Hansen, A. M. K., Vienberg, S. G., Lykkegaard, K., Zhao, X., Tingqing, G., Han, D., Zhang, X., Thøgersen, H., Sass‐Ørum, K., Tagmose, T. M., et al. (2018) · Biochemical Journal · doi:10.1042/bcj20180555 · Cited by 23 · see citing works

REV-ERBα regulates Fgf21 expression in the liver via hepatic nuclear factor 6

Chavan, R., Preitner, N., Okabe, T., Mansencal-Strittmatter, L., Xu, C., Ripperger, J. A., Pitteloud, N., & Albrecht, U. (2016) · Biology Open · doi:10.1242/bio.021519 · Cited by 21 · see citing works

Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting

Antonellis, P. J., Hayes, M. P., & Adams, A. C. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00077 · Cited by 17 · see citing works

Impact of weight loss on health-related quality of life

Bartlett, S. J., & Cheskin, L. J. (1999) · Cited by 17 · see citing works

炭水化物摂取を抑制する腹内側視床下部におけるグルタミン酸作動性ニューロンへのFGF21シグナル【JST・京大機械翻訳】

Sharon, O., Kyle, H. F., Kristin, E. C., Yavuz, Y., Sarah, A. S., Grant, C., Yuriy, M. U., Atasoy, D., Matthew, P., & Matthew, J. P. (2020) · Cell Metabolism · Cited by 15 · see citing works

The islet-expressed Lhx1 transcription factor interacts with Islet-1 and contributes to glucose homeostasis

Bethea, M. M., Liu, Y., Wade, A. K., Mullen, R. D., Gupta, R., Gelfanov, V. M., DiMarchi, R. D., Bhatnagar, S., Behringer, R. R., Habegger, K. M., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00235.2018 · Cited by 14 · see citing works

Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21

Pan, J. B., Parlee, S. D., Brunel, F. M., Li, P., Lu, W., Pérez–Tilve, D., Liu, F., Finan, B., Kharitonenkov, A., & DiMarchi, R. D. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00100 · Cited by 9 · see citing works

Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues

Geng, L. (2018) · doi:10.5353/th_991044040574003414 · Cited by 9 · see citing works

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 147 · see citing works

New developments in the biology of fibroblast growth factors

Ornitz, D. M., & Itoh, N. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1549 · Cited by 143 · see citing works

The molecular pharmacology of glucagon agonists in diabetes and obesity

Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82 · see citing works

Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?

Conceição-Furber, E., Coskun, T., Sloop, K. W., & Samms, R. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.868037 · Cited by 48 · see citing works

Cross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte

Habegger, K. M. (2022) · Diabetes · doi:10.2337/dbi22-0002 · Cited by 40 · see citing works

Fibroblast growth factor 21: An emerging pleiotropic regulator of lipid metabolism and the metabolic network

Li, S., Zou, T., Chen, J., Li, J., & You, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.033 · Cited by 37 · see citing works

Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells

Elmelund, E., Galsgaard, K. D., Johansen, C. D., Trammell, S. A. J., Bomholt, A. B., Winther‐Sørensen, M., Hunt, J. E., Sørensen, C. M., Kruse, T., Lau, J. F., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105296 · Cited by 32 · see citing works

A GLP‐1/glucagon (GCG)/CCK₂ receptors tri‐agonist provides new therapy for obesity and diabetes

Zhao, S., Yan, Z., Du, Y., Li, Z., Tang, C., Jing, L., Sun, L., Yang, Q., Tang, X., Yuan, Y., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15860 · Cited by 30 · see citing works

The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk

Valdecantos, M. P., Ruiz, L., Folgueira, C., Rada, P., Gómez‐Santos, B., Solas, M., Hitos, A. B., Field, J., Francisco, V., Escalona-Garrido, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54080-w · Cited by 22 · see citing works

Oxyntomodulin physiology and its therapeutic development in obesity and associated complications

Kueh, M. T. W., Chong, M. C., Miras, A. D., & le Roux, C. W. (2024) · The Journal of Physiology · doi:10.1113/jp287407 · Cited by 19 · see citing works

Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice

Galsgaard, K. D., Elmelund, E., Johansen, C. D., Bomholt, A. B., Kizilkaya, H. S., Ceutz, F. R., Hunt, J. E., Kissow, H., Winther‐Sørensen, M., Sørensen, C. M., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101639 · Cited by 19 · see citing works

Intermittent protein restriction protects islet β cells and improves glucose homeostasis in diabetic mice

Wei, S., Li, C., Luo, X., Yang, L., Yu, L., Wang, Q., Meng, Z., Wang, T., & Chen, Y. (2021) · 中国科学通报：英文版 · doi:10.1016/j.scib.2021.12.024 · Cited by 16 · see citing works

Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy

Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16 · see citing works

Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 15 · see citing works

Constitutively active glucagon receptor drives high blood glucose in birds

Zhang, C., Xiang, X., Liu, J., Huang, Y., Xue, J., Sun, Q., Leng, S., Liu, S., He, X., Hu, P., et al. (2025) · Nature · doi:10.1038/s41586-025-08811-8 · Cited by 14 · see citing works

GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice

Laker, R. C., Egolf, S., Will, S., Lantier, L., McGuinness, O. P., Brown, C. L., Bhagroo, N. V., Oldham, S. N., Kuszpit, K. K., Alfaro, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59773-4 · Cited by 13 · see citing works

β-Klotho as novel therapeutic target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A narrative review

Meroni, M., Dongiovanni, P., Tiano, F., Piciotti, R., Alisi, A., & Panera, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117608 · Cited by 13 · see citing works

RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis

Jamaluddin, A., & Gorvin, C. M. (2023) · Journal of Molecular Endocrinology · doi:10.1530/jme-23-0014 · Cited by 11 · see citing works

Characterization of LY3324954 a long-acting glucagon-receptor agonist

Roell, W. C., Coşkun, T., Kim, T., O’Farrell, L. S., Martin, J. A., Nason, S. R., Hernandez-Alamillo, J., Dhantu, S., Drucker, D. J., Sloop, K. W., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102073 · Cited by 11 · see citing works

Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus

Prajapati, A., Rana, D., Rangra, S., Jindal, A. B., & Benival, D. M. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10590-1 · Cited by 10 · see citing works

Impaired Fat Absorption from Intestinal Tract in High-Fat Diet Fed Male Mice Deficient in Proglucagon-Derived Peptides

Nishida, K., Ueno, S., Seino, Y., Hidaka, S., Murao, N., Asano, Y., Fujisawa, H., Shibata, M., Takayanagi, T., Ohbayashi, K., et al. (2024) · Nutrients · doi:10.3390/nu16142270 · Cited by 9 · see citing works

Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes

Wu, Y., Chan, A. Y., Hauke, J., Aung, O. H., Foollee, A., Cleofe, M. A. S., Stölting, H., Han, M., Jeppe, K. J., Barlow, C. K., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102064 · Cited by 9 · see citing works

CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects

Zheng, Y., Wang, Y., Xiong, X. B., Zhang, L., Zhu, J., Huang, B., Liu, X., Liu, J., Zhu, Z., Yang, G., et al. (2024) · Advanced Science · doi:10.1002/advs.202400819 · Cited by 6 · see citing works

Hepatic TORC2 Signaling Facilitates Acute Glucagon-Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice

Kim, T., Nason, S. R., ANTIPENKO, J. P., Finan, B., Shalev, A., DiMarchi, R. D., & Habegger, K. M. (2022) · Diabetes · doi:10.2337/db21-1018 · Cited by 6 · see citing works

Pancreatic hormones: insulin and glucagon

Litwack, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90262-5.00022-6 · Cited by 5 · see citing works

The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition

Moreno-Lopez, M., Louvet, I., Delalleau, N., Acosta-Montalvo, A., Thévenet, J., Pasquetti, G., Gmyr, V., Kerr-Conte, J. A., Pattou, F. N., Bonner, C., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16089 · Cited by 4 · see citing works

From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity

Kistkins, S., Moser, O., Ankudovičs, V., Bļizņuks, D., Mihailovs, T., Lobanovs, S., Sourij, H., Pfeiffer, A. F. H., & Pīrāgs, V. (2024) · Endocrine Connections · doi:10.1530/ec-23-0529 · Cited by 2 · see citing works

Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies

Abburi, K., Melson, E., Miras, A. D., & Papamargaritis, D. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05339-x · Cited by 1 · see citing works

Avian GCGR-mediated continuous fat utilization offers perspectives for obesity treatment

Zhang, C., Wang, X. B., Feng, C., Zheng, H., Leng, S., Jiang, Y., Sun, Q., Li, X., Zhang, T., Zhang, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66305-7 · Cited by 1 · see citing works

Development of a severe rat refeeding syndrome model and mathematical modeling of the associated hypophosphatemia

Kato, H., Yamaoka, I., & Kubota, H. (2026) · npj Systems Biology and Applications · doi:10.1038/s41540-026-00658-7 · Cited by 1 · see citing works

Mazdutide: An emerging glucagon/GCG-like peptide-1 dual receptor agonist for obesity—a comparison of therapeutic effects and potential side effects with GCG-like peptide-1 inhibitors

Deng, C.-X., Chen, Z.-M., Tang, Y.-X., Xi, Z.-X., Wang, S.-Y., Wu, H.-Y., Xu, B., & Xu, T.-C. (2026) · World Journal of Pharmacology · doi:10.5497/wjp.v15.i1.113080

Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework

Kaczynski, M., Zureikat, R. M., Kaczynski, M. R., Sitarz, R., & Karakuła‐Juchnowicz, H. (2026) · Biomedicines · doi:10.3390/biomedicines14091957

GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity–Neurodegeneration Interface: A Narrative Review

Popa, E., Popa, A. E., Poroch, V., Schreiner, T. G., Slănină, A. M., Poroch, M., Hatneanu, A. M., Ungureanu, M. I., Petroaie, A. D., Bacușcă, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198738

Glucagon Regulates Energy Balance via FGF21 Signaling in the Brain

Presedo, N., Kim, T., Nason, S. R., ANTIPENKO, J. P., Finan, B., DiMarchi, R. D., & Habegger, K. M. (2020) · The FASEB Journal · doi:10.1096/fasebj.2020.34.s1.03065

Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets

Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Besing, G.-L. K., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101718 · Cited by 48 · see citing works

Pharmacological FGF21 signals to glutamatergic neurons to enhance leptin action and lower body weight during obesity

Claflin, K. E., Sullivan, A. I., Naber, M. C., Flippo, K. H., Morgan, D. A., Neff, T. J., Jensen-Cody, S. O., Zhu, Z., Zingman, L. V., Rahmouni, K., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101564 · Cited by 37 · see citing works

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245 · see citing works

Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate DietsPreprint

Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., Koehler, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.03.522509 · Cited by 2 · see citing works